How can proton pump inhibitors damage central and peripheral nervous systems?

por Makunts, Tigran, Abagyan, Ruben
Publicado 2020

Anti-TNF-α therapy induced psoriasis in rheumatoid arthritis patients according to FDA postmarketing surveillance data

por Joulfayan, Haroutyun, Makunts, Tigran, Abagyan, Ruben
Publicado 2023

Common osteoporosis drug associated with increased rates of depression and anxiety

por Keshishi, Dro, Makunts, Tigran, Abagyan, Ruben
Publicado 2021

Postmarketing safety surveillance data reveals antidepressant effects of botulinum toxin across various indications and injection sites

por Makunts, Tigran, Wollmer, Marc Axel, Abagyan, Ruben
Publicado 2020

Retrospective analysis reveals significant association of hypoglycemia with tramadol and methadone in contrast to other opioids

por Makunts, Tigran, U, Andrew, Atayee, Rabia S., Abagyan, Ruben
Publicado 2019

Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events

por Makunts, Tigran, Burkhart, Keith, Abagyan, Ruben, Lee, Peter
Publicado 2022

Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications

por Cohen, Isaac V., Makunts, Tigran, Atayee, Rabia, Abagyan, Ruben
Publicado 2017

Publisher Correction: Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications

por Cohen, Isaac V., Makunts, Tigran, Atayee, Rabia, Abagyan, Ruben
Publicado 2017

Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis

por Makunts, Tigran, Cohen, Isaac V., Awdishu, Linda, Abagyan, Ruben
Publicado 2019

Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database

por Cohen, Isaac V., Makunts, Tigran, Abagyan, Ruben, Thomas, Kelan
Publicado 2021

Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database

por Makunts, Tigran, Jerome, Lisa, Abagyan, Ruben, de Boer, Alberdina
Publicado 2022

Population scale retrospective analysis reveals distinctive antidepressant and anxiolytic effects of diclofenac, ketoprofen and naproxen in patients with pain

por Makunts, Tigran, Cohen, Isaac V., Lee, Kelly C., Abagyan, Ruben
Publicado 2018

Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting system

por Makunts, Tigran, Dahill, Diane, Jerome, Lisa, de Boer, Alberdina, Abagyan, Ruben
Publicado 2023

Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory

por Makunts, Tigran, Alpatty, Sama, Lee, Kelly C., Atayee, Rabia S., Abagyan, Ruben
Publicado 2019

Postmarketing safety surveillance data reveals protective effects of botulinum toxin injections against incident anxiety

por Wollmer, M. Axel, Makunts, Tigran, Krüger, Tillmann H. C., Abagyan, Ruben
Publicado 2021

Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports

por Cohen, Isaac V., Makunts, Tigran, Moumedjian, Talar, Issa, Masara A., Abagyan, Ruben
Publicado 2020

Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data

por Makunts, Tigran, Saunders, Ila M., Cohen, Isaac V., Li, Mengxing, Moumedjian, Talar, Issa, Masara A., Burkhart, Keith, Lee, Peter, Patel, Sandip Pravin, Abagyan, Ruben
Publicado 2021